Jun 24, 2023 / 04:30PM GMT
Paul A. Friedman - Madrigal Pharmaceuticals, Inc. - CEO & Director
So good evening, and thanks for joining Madrigal's EASL Investor Event and Webcast. With me today in Vienna are Dr. Becky Taub, President of R&D and Chief Medical Officer; and Dr. Stephen Harrison, lead investigator of our Phase III MISO studies of resmetirom. Fine print. These are our forward-looking statements. I'd ask you to see Thursday's press release and our recent SEC filings for risk factor considerations associated with these statements and our business. We'd like to express our thanks to EASL for selecting -- the pivotal Phase III MAESTRO-NASH trial of resmetirom is the first abstract to open Thursday general session of the Congress. The presentation signaled an important milestone for Madrigal and the Nash field. And based on the positive feedback and words of encouragement we received from thought leaders, community clinicians and our other stakeholders after the presentation. I believe that the MAESTRO-NASH data set the tone for the meeting.
Before Becky and Stephen Harrison review the detailed that, I'd like
Madrigal Pharmaceuticals Inc Phase 3 MAESTRO-NASH Trial Investor Call Transcript
Feb 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers